Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • On-treatment virologic response is predictive of SVR with older DAA regimens
    • Undetectable HCV RNA at Week 4 (RVR) is a positive predictor of SVR with boceprevir or telaprevir + peginterferon[Poordad 2011; Jacobson 2011a]
    • Detectable HCV RNA at Week 12 is a negative predictor of SVR to boceprevir or telaprevir + peginterferon[Poordad 2011; Jacobson 2011a]

Action required

Keywords: Hepatitis C-Treatment

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.